Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial

OBJECTIVE: To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyomas. METHODS: This double-blind, randomized, placebo-control...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Obstet Gynecol
Autori principali: Carr, Bruce R., Stewart, Elizabeth A., Archer, David F., Al-Hendy, Ayman, Bradley, Linda, Watts, Nelson B., Diamond, Michael P., Gao, Jingjing, Owens, Charlotte D., Chwalisz, Kristof, Duan, W. Rachel, Soliman, Ahmed M., Dufek, Matthew B., Simon, James A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7963450/
https://ncbi.nlm.nih.gov/pubmed/30303923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/AOG.0000000000002933
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi